← Search & browse all drugs
SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Antiinflammatory agents, non-steroids
nepafenac
S01BC10
Forms & Strengths
- Ophthalmic suspension 0.1%
- Ophthalmic suspension 0.3%
Adult Dosing
- 0.1% suspension: 1 drop into the affected eye 3 times daily beginning 1 day prior to cataract surgery and continuing through the first 2 weeks of the postoperative period
- 0.3% suspension: 1 drop into the affected eye once daily beginning 1 day prior to cataract surgery, continuing on the day of surgery, and through the first 2 weeks of the postoperative period
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of pain and inflammation associated with cataract surgery
Mechanism of Action
- Nonsteroidal anti-inflammatory drug (NSAID) that penetrates the cornea and is converted by intraocular hydrolases to amfenac, a potent inhibitor of prostaglandin H synthase (cyclooxygenase 1 and 2), reducing the production of inflammatory prostaglandins
Contraindications
- Hypersensitivity to nepafenac or any component of the formulation
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Adverse Reactions
- Increased intraocular pressure
- Capsular opacification
- Decreased visual acuity
- Foreign body sensation
- Keratitis
- Eyelid margin crusting
- Conjunctival hyperemia
Drug Interactions
- Prostaglandin analogues (may potentially decrease the effect of prostaglandin analogues or vice versa; use with caution)
- Topical corticosteroids (concurrent use may increase the potential for healing delays)
Curated Content: Needs Vetting Before Put to Clinical Use